RXRX - Mergers and acquisitions

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's (NASDAQ:RLYB) full interest in their joint ENPP1 inhibitor program (REV102) and an associated backup molecule for the treatment of hypophosphatasia (HPP), a rare and debilitating genetic disorder. "We extend our sincere thanks to Rallybio for their invaluable partnership in advancing this program to its current stage," said David Hallett, Chief Scientific Officer of Recursion. "Having full ownership of this important program allows Recursion to accelerate the development of the first

USA News Group Commentary VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings,

SALT LAKE CITY, July 1, 2021 /PRNewswire/ -- Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and office space as well as 1,200 multifamily units.